Skip to content
LIVE
The Executives BriefThe Executives Brief

The new top fear in America isn't cancer. It's AI.

An opinion piece in The Hill argues the anxiety has moved from mortality to livelihood, and that changes how executives should sequence automation.

ByLama Al-RashidTechnology Correspondent, The Executives Brief
·3 min read
The new top fear in America isn't cancer. It's AI.
Executive summary

An opinion piece published by The Hill argues that Americans increasingly fear the societal and economic disruption caused by artificial intelligence more than they fear terminal cancer. For decision-makers, that shift means AI rollouts will be judged on jobs, trust, and timing rather than on capability alone.

An opinion piece published by The Hill argues that Americans increasingly fear the societal and economic disruption caused by artificial intelligence more than they fear terminal cancer. Read that again, because the ranking is the story. Cancer has historically been the dread that sits at the top of public fear surveys, the diagnosis that organizes fundraising, screening campaigns, and a huge share of medical research spending. The argument in The Hill is that AI has now displaced it in the public imagination, not because cancer got less frightening, but because AI feels like a threat that is arriving faster and that nobody has agreed to stop.

The distinction matters because the two fears are structurally different. Fear of cancer is fear of biology, of something that happens to you. Fear of AI, as the piece frames it, is fear of decisions other people make: which jobs get automated, which tasks get handed to a model, which workers get retrained and which get a severance package. One is a medical problem with a research pipeline attached. The other is a governance problem with a boardroom attached. That is why the shift is a business story, not just a cultural one.

Three forces typically drive this kind of anxiety shift. First, visibility: AI arrived in consumer products fast, so people formed opinions before institutions formed policies. Second, proximity: the disruption is framed around work, and work is where identity, income, and health insurance live. Third, agency: cancer fear comes with a script (screen, treat, fund research), while AI fear comes with no agreed script at all. When a threat has no script, people default to the loudest available narrative, and the loudest narratives about AI have generally been about replacement.

Regulators have not filled that vacuum evenly. The European Union moved first with a broad AI rulebook that sorts applications by risk. In the United States, oversight has generally arrived in patches: executive orders that shift with administrations, agency guidance, and a growing stack of state-level bills. For executives, that patchwork is the practical consequence of the fear ranking. Public anxiety is political fuel, and political fuel tends to produce disclosure requirements, audit obligations, and hiring rules that land on companies long before they land on the technology itself.

Meanwhile the money keeps moving. AI has shifted from pilot project to budget line at most large companies, and the spending is typically justified on productivity: faster code, cheaper support, shorter research cycles. That justification is exactly what makes the fear rational rather than hysterical. Productivity gains have to come from somewhere, and in most operating models the somewhere is headcount, vendor contracts, or both. A workforce that has watched previous automation waves knows the pattern, and it does not need a forecast to feel the direction of travel.

The second-order effects are where this gets expensive. If fear is the binding constraint on adoption, then the constraint is not compute, data, or talent. It is trust. Companies that announce AI programs without naming who is affected tend to get the worst version of the story told about them, usually by their own employees. Companies that name the affected roles, publish the retraining numbers, and put a timeline on the change tend to absorb the same disruption with far less reputational damage. The asymmetry is brutal and it is predictable.

None of this argues for slowing down. It argues for sequencing. The practical playbook looks unglamorous: decide which tasks change first, tell the people who do those tasks before the press release, fund the retraining before the savings show up, and measure adoption by whether the work actually improved rather than by how many seats were removed. Boards should also treat public sentiment as a risk register item, not a communications chore. A fear that outranks cancer in the public imagination is a leading indicator of political attention, and political attention eventually becomes law.

The strategic stakes for peers are straightforward. Every operator in every sector is now running the same experiment: how much automation can you deploy before the people around you decide you are the problem? The Hill's argument suggests the tolerance threshold is lower than most leadership teams assume, and that the cost of getting the sequencing wrong is measured in trust, hiring, and regulatory scrutiny rather than in a single bad quarter. The companies that treat that as a design constraint, rather than a PR problem, will be the ones still deploying when the fear cycle turns.

Executive ActionsLocked

This story's Key Insights and Take-aways are locked.

Create a free account to unlock Executive Actions for one credit.

Register to Unlock

Always free for Executives Club members. Join the Club

More in Politics